Healthcare / BiotechnologyTokyo
$222.00
+2.00 (+0.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.0B · quality 74.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.0B
P/E
N/A
•EV/EBITDA
8.4x
↓ROE
-7.4%
↓Gross Margin
22.8%
↓Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.3%
FCF CAGR
-28.2%
FCF margin
5.6%
FCF / Net income
-1.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.44B · net income $-539.1M · FCF $586.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.44B | $10.44B | $12.31B | $12.52B | $11.56B |
| Net Income | $-539.1M | $-539.1M | $338.3M | $1.00B | $790.5M |
| EBITDA | $35.9M | $35.9M | $1.20B | $1.89B | $1.49B |
| EPS | -23.87 | -23.87 | 14.98 | 44.47 | 35.00 |
| Gross Margin | 22.8% | 22.8% | 30.7% | 33.2% | 31.3% |
| Operating Margin | -5.6% | -5.6% | 5.9% | 10.0% | 9.4% |
| Net Margin | -5.2% | -5.2% | 2.7% | 8.0% | 6.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.32 | 0.32 | 0.35 | 0.47 | 0.63 |
| Current Ratio | 1.31 | 1.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $586.8M | $586.8M | $1.03B | $1.83B | $1.59B |
| Returns | |||||
| ROE | -7.4% | -7.4% | 4.1% | 13.2% | 12.1% |
| Valuation | |||||
| P/E | — | — | 25.63 | 15.18 | 24.69 |
| EV/EBITDA | 8.43 | 8.43 | 3.43 | 6.21 | 11.86 |
| P/B | 0.69 | 0.69 | 1.05 | 2.01 | 2.98 |
| Growth & Yield | |||||
| Revenue Growth | -15.2% | -15.2% | -1.7% | 8.3% | — |
| EPS Growth | -259.3% | -259.3% | -66.3% | 27.1% | — |
| Dividend Yield | 7.2% | 7.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.5%
Start / end P/E
n/dx → n/dx
EPS bridge
14.98 → -23.87
Residual
-26.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.